Home
CATX
CATX News

Latest Perspective Therapeutics Inc. (CATX) News on November 24, 2025

Associated Press Finance

13 days ago

Perspective Therapeutics: Q3 Earnings Snapshot

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

GlobeNewswire

13 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Zacks

18 days ago

Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates

Zacks

19 days ago

Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

GlobeNewswire

a month ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Could CATX’s New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy?

Simply Wall St.

a month ago

Could CATX’s New ESMO Data Reveal a Shift in Its Long-Term Oncology Innovation Strategy?

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

GlobeNewswire

4 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

MT Newswires

5 months ago

B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

GlobeNewswire

5 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

GlobeNewswire

5 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

3 Promising Penny Stocks With Market Caps Over $90M

Simply Wall St.

6 months ago

3 Promising Penny Stocks With Market Caps Over $90M

MT Newswires

6 months ago

RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

GlobeNewswire

6 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential

Insider Monkey

6 months ago

Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential

MT Newswires

6 months ago

Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating

Associated Press Finance

6 months ago

Perspective Therapeutics: Q1 Earnings Snapshot

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

GlobeNewswire

6 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

GlobeNewswire

7 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

MT Newswires

7 months ago

Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

GlobeNewswire

7 months ago

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

GlobeNewswire

7 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?

Zacks

7 months ago

Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

GlobeNewswire

7 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

MT Newswires

7 months ago

Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire

7 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

MT Newswires

8 months ago

Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround

Zacks

8 months ago

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

GlobeNewswire

8 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

MT Newswires

8 months ago

RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

GlobeNewswire

8 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

MT Newswires

8 months ago

Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire

8 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

MT Newswires

8 months ago

HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target

MT Newswires

8 months ago

Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target

LNTH: 2025 Guidance Provided

Zacks Small Cap Research

9 months ago

LNTH: 2025 Guidance Provided

Perspective Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire

9 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

GlobeNewswire

9 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

GlobeNewswire

10 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

MT Newswires

10 months ago

Sector Update: Health Care

Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars

Benzinga

10 months ago

Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars

MT Newswires

10 months ago

Perspective Therapeutics Says Updated Interim Findings From Phase 1/2a Study Support Further Dose-Finding Research

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire

10 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

GlobeNewswire

10 months ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

Perspective Therapeutics provides business updates, strategic priorities

TipRanks

10 months ago

Perspective Therapeutics provides business updates, strategic priorities

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

a year ago

Perspective Therapeutics Appoints Juan Graham as CFO; Shares Fall

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

GlobeNewswire

a year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

GlobeNewswire

a year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

MT Newswires

a year ago

B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating

Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital

TipRanks

a year ago

Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital

Perspective Therapeutics downgraded to Neutral from Buy at BofA

TipRanks

a year ago

Perspective Therapeutics downgraded to Neutral from Buy at BofA

MT Newswires

a year ago

BofA Securities Downgrades Perspective Therapeutics to Neutral From Buy, Price Target is $6

MT Newswires

a year ago

RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk

MT Newswires

a year ago

Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

GlobeNewswire

a year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?

Insider Monkey

a year ago

Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025?

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

GlobeNewswire

a year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

MT Newswires

a year ago

RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk

Associated Press Finance

a year ago

Perspective Therapeutics: Q3 Earnings Snapshot

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

GlobeNewswire

a year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

GlobeNewswire

a year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

MT Newswires

a year ago

UBS Initiates Perspective Therapeutics at Buy With $20 Price Target

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire

a year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

MT Newswires

a year ago

Perspective Therapeutics Makes First Shipment of Investigational Products From New Jersey Facility

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

GlobeNewswire

a year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies

Insider Monkey

a year ago

Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies

MT Newswires

a year ago

Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating

MT Newswires

a year ago

Perspective Therapeutics Says Initial Data Show Potential Melanoma Therapy's Safety, Efficacy

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

GlobeNewswire

a year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

GlobeNewswire

a year ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

GlobeNewswire

a year ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

MT Newswires

a year ago

Wedbush Initiates Perspective Therapeutics at Outperform With $25 Price Target

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire

a year ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

MT Newswires

a year ago

Update: Truist Initiates Perspective Therapeutics at Buy With $21 Price Target

MT Newswires

a year ago

Truist Initiates Perspective Therapeutics at Buy

Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024

GlobeNewswire

a year ago

Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024

MT Newswires

a year ago

Perspective Therapeutics Gets FDA Fast Track Label for VMT01 to Treat Melanoma; Shares Rise

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

GlobeNewswire

a year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewswire

a year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

MT Newswires

a year ago

RBC Adjusts Perspective Therapeutics' PT to $27 From $29, Keeps Outperform Rating, Speculative Risk

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

MT Newswires

a year ago

Oppenheimer Adjusts Perspective Therapeutics Price Target to $17 From $19, Maintains Outperform Rating

Associated Press Finance

a year ago

Perspective Therapeutics: Q2 Earnings Snapshot

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

GlobeNewswire

a year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

GlobeNewswire

a year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

MT Newswires

a year ago

BofA Securities Starts Perspective Therapeutics With Buy Rating, $24 Price Target

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer Wednesday Afternoon

MT Newswires

a year ago

Perspective Therapeutics to Join Russell 3000 Index on July 1

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

GlobeNewswire

a year ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

MT Newswires

a year ago

Perspective Therapeutics to Reverse Split Common Shares

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

GlobeNewswire

a year ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

GlobeNewswire

a year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

MT Newswires

a year ago

Perspective Therapeutics Prices $80 Million Share, Warrant Offering

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

a year ago

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

GlobeNewswire

2 years ago

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

MT Newswires

2 years ago

Perspective Therapeutics Swings to Loss in Q1, Revenue Rises

Share on Social Networks: